Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 41Neoplasm Metastasis 11Hereditary Sensory and Autonomic Neuropathies 6Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Ovarian Neoplasms 5Neoplasms 5Triple Negative Breast Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Head and Neck Neoplasms 3Pancreatic Neoplasms 2Melanoma 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Lymphangioma 2Hyperglycemia 2Head and Neck Squamous Cell Cancer 2Endometrial Neoplasms 2Colorectal Neoplasms 2Advanced Breast Cancer 2Vascular Malformations 1Uveal Melanoma 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Stomach Neoplasms 1Solid Tumor 1Skin Diseases, Vascular 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pre-menopausal Breast Cancer 1

Interventions

Cisplatin 56Radiotherapy 34Radiotherapy, Intensity-Modulated 28Magnetic Resonance Spectroscopy 24Radiation 20Carboplatin 19pembrolizumab 17Specimen Handling 16Platinum 141,2-diaminocyclohexaneplatinum II citrate 14Paclitaxel 13Cetuximab 13Fluorouracil 10Surgical Procedures, Operative 9Docetaxel 9Biopsy 9Taxes 8Chemoradiotherapy 8Nivolumab 7Fluorodeoxyglucose F18 7Drug Therapy 7durvalumab 6Surveys and Questionnaires 6fludarabine 5X-Rays 5Observation 5Cyclophosphamide 5aldesleukin 4Standard of Care 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Oropharyngeal Neoplasms × Alpelisib × Clear all
NCT02298595 2017-11-13

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

University of Pittsburgh

Phase 1/2 Withdrawn
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡